

Aeglea BioTherapeutics brings Dr. Bryan Lawlis on Board

17 July 2018 | News

Dr. Lawlis has a B.A. in microbiology from the University of Texas at Austin and a Ph.D. in biochemistry from Washington State University. Dr. Lawlis was a National Institutes of Health postdoctoral fellow at Kansas State University and holds 13 patents in the United States.



Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics for patients with rare genetic diseases and cancer, today announced the appointment of Bryan Lawlis, Ph.D., to its Board of Directors, effective immediately.

"We are delighted to welcome Dr. Lawlis to our Board, Bryan is a seasoned biotechnology industry executive who brings a tremendous amount of manufacturing and process development expertise," said Anthony G. Quinn, M.B Ch.B, Ph.D., interim chief executive officer of Aeglea. "Bryan's operational and board experience includes time with both growth-stage and large-scale biotechnology companies, and we look forward to his input and guidance as we advance our clinical trials and pipeline."

"This is an exciting time to be joining Aeglea as it moves forward with its lead development program, pegzilarginase, particularly in light of the recently announced clinically relevant treatment effects with respect to Arginase 1 Deficiency," said Dr. Lawlis. "I look forward to working with the Board as the Company develops its research pipeline of enzyme-based therapeutics."

Dr. Lawlis served as CEO of Itero LLC from 2011 to 2017 and from 2007 to 2011 was co-founder and CEO of Itero BioPharmaceuticals, Inc. Before that, he held roles of COO, president and CEO of Aradigm Corporation from 2001 to 2006. From 1996 to 2001, Dr. Lawlis co-founded Covance Biotechnology Services and held the positions of president, CEO and executive chairman. Dr. Lawlis worked at Genentech from 1981 to 1996 where he rose to the position of vice president of process science. Dr. Lawlis's current board appointments include independent directorships at Biomarin Pharmaceutical, Geron Corporation, and Coherus Biosciences.

Dr. Lawlis has a B.A. in microbiology from the University of Texas at Austin and a Ph.D. in biochemistry from Washington State University. Dr. Lawlis was a National Institutes of Health postdoctoral fellow at Kansas State University and holds 13 patents in the United States.